Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “TB0001 is a sterile, clear colorless to slightly yellow pregabalin ophthalmic solution at concentrations of 0.9%”In the company’s words, NCT07913074 on ClinicalTrials.gov
- Tested for
- Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT)
- Main trialPhase 2
- “This study is evaluating a new eye drop containing pregabalin (TB0001) as a potential treatment for people with primary open-angle glaucoma or ocular hypertension. The study aims to determine whether TB0001 lowers eye pressure as effectively as timolol, a commonly used glaucoma eye drop, while remaining safe and well tolerated. Participants will be randomly assigned to receive one of three strengths of TB0001 or timolol for 28 days. Eye pressure, eye health, side effects and tolerability will be assessed throughout the study. The results will help identify the most appropriate dose of TB0001…”In the company’s words, NCT07913074 on ClinicalTrials.gov
Other drugs for Ocular Hypertension (OHT)
- Bimatoprost ophthalmic 0.01% YSBPYS Life Science Co., Ltd. · Phase 3
- HUC3-637Huons Co., Ltd. · Phase 3
- Gen 2 Travoprost Intracameral ImplantGlaukos Corporation · Phase 3
- Product DNN.31.19.026Ache Laboratorios Farmaceuticos S.A. · Phase 3
- Citicoline eye drops 2%Omikron Italia S.r.l. · Phase 3
- Bimatoprost 0.01% OphthalmicAmneal Pharmaceuticals, LLC · Phase 3
Coming up1
- 30 Jun 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 30 Jun 2027 | A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026